For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Apellis Pharmaceuticals, Inc.

USPTO Granted Patents = 27

% Expired Patents = 3.7

EPO Patents = 8

Trademarks = 9

Forward Citations = 188

Loading Chart...

Loading Chart...

10 inventors (with patents filed for the assignee):

Cedric Francois (25 out of 43 patents)

Pascal Deschatelets (23 out of 31 patents)

Federico Grossi (5 out of 5 patents)

4. Patrick Johnson (4 out of 4 patents)

5. Carolina Vega (4 out of 4 patents)

6. Monica Gerber (3 out of 4 patents)

7. Lukas Scheibler (3 out of 18 patents)

8. Paul Olson (3 out of 24 patents)

9. Christian Mueller (2 out of 27 patents)

10. Zhouning Zhang (1 out of 1 patent)

Core Competencies:

Viral Vector Therapy

Complement Inhibition

Compstatin Analogs

Dosing Regimens

Chronic Disorders

Combination Therapy

RNA Therapeutics

Complement-Mediated Disorders

Detection of Drusen

Cell-Reactive Analogs

Targeted Therapies

Neuropathic Pain

27 patents: Sort by Forward Citations

1. 12741036 - VIRAL VECTOR THERAPY (2026-09-22),

2. 12458695 - Dosing regimens and related compositions and methods (2025-11-04),

3. 12290566 - Dosing regimens and related compositions and methods (2025-05-06),

4. 12251395 - RNAS for complement inhibition (2025-03-18),

5. 11903994 - Dosing regimens (2024-02-20),

6. 11844841 - Dosing regimens and related compositions and methods (2023-12-19),

7. 11712460 - Methods of treating chronic disorders with complement inhibitors (2023-08-01),

8. 11661441 - Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof (2023-05-30),

9. 11510939 - RNAs for complement inhibition (2022-11-29),

10. 11407789 - Cell-penetrating compstatin analogs and uses thereof (2022-08-09),

11. 11338013 - Combination therapy for C3 inhibition (2022-05-24),

12. 11292815 - Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods (2022-04-05),

13. 11291407 - Detection of high risk drusen (2022-04-05),

14. 11040107 - Dosing regimens and related compositions and methods (2021-06-22),

15. 11013782 - Methods of treating chronic disorders with complement inhibitors (2021-05-25),

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company based in Waltham, MA, focused on developing innovative therapies for patients with rare diseases. The company specializes in complement inhibition, a critical area of research aimed at addressing various autoimmune and inflammatory conditions. Apellis is dedicated to advancing its pipeline of novel treatments that target the underlying mechanisms of disease, thereby improving patient outcomes and quality of life.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Apellis Pharmaceuticals, Inc.

27 Patents

#58 in Waltham, MA

#740 in Massachusetts

#12,410 in US

#23,984 in the World

Waltham, MA, United States of America

Apellis Pharmaceuticals, Inc.

Forward Citations = 188

10 inventors:

Cedric Francois (25 out of 43 patents)

Pascal Deschatelets (23 out of 31 patents)

Federico Grossi (5 out of 5 patents)

4. Patrick Johnson (4 out of 4 patents)

5. Carolina Vega (4 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…